Fitzpatrick Alexander A 4
4 · ARS Pharmaceuticals, Inc. · Filed Jun 12, 2026
Research Summary
AI-generated summary of this filing
ARS (SPRY) Chief Legal Officer Alexander Fitzpatrick Sells 3,355 Shares
What Happened
Alexander A. Fitzpatrick, Chief Legal Officer of ARS Pharmaceuticals (SPRY), sold 3,355 shares on June 12, 2026 at $10.00 per share, generating proceeds of $33,550. The transaction was a sale (S) executed pursuant to a pre-established Rule 10b5-1 trading plan.
Key Details
- Transaction date and price: 2026-06-12, 3,355 shares sold at $10.00 each (total $33,550).
- Transaction type/code: Open market sale (S), executed under a Rule 10b5-1 plan adopted December 5, 2025 (Footnote F1).
- Shares owned after transaction: Not specified in the provided filing.
- Footnote on holdings (F2): Reporting person’s holdings include ESPP purchases — 2,907 shares acquired 2025-06-30 and 1,745 shares acquired 2025-12-31.
- Filing timeliness: Report filed on the same date (2026-06-12); no late filing indicated.
Context
Sales made under a 10b5-1 plan are typically pre-scheduled and may not reflect the insider’s current view of the company. For retail investors, purchases generally provide stronger signals than routine plan-based sales; this single sale is relatively small in dollar terms.
Insider Transaction Report
Form 4
Fitzpatrick Alexander A
Chief Legal Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-06-12$10.00/sh−3,355$33,550→ 90,910 total
Footnotes (2)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
- [F2]Includes 2,907 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2025 and 1,745 shares acquired under the ESPP on December 31, 2025.
Signature
/s/ Kathleen Scott, Attorney-in-Fact|2026-06-12